KR100736517B1 - 장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 - Google Patents
장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 Download PDFInfo
- Publication number
- KR100736517B1 KR100736517B1 KR1020060047726A KR20060047726A KR100736517B1 KR 100736517 B1 KR100736517 B1 KR 100736517B1 KR 1020060047726 A KR1020060047726 A KR 1020060047726A KR 20060047726 A KR20060047726 A KR 20060047726A KR 100736517 B1 KR100736517 B1 KR 100736517B1
- Authority
- KR
- South Korea
- Prior art keywords
- idcc
- lactobacillus
- bacteria
- strain
- food
- Prior art date
Links
- OGQHCUYSWDOIMP-UHFFFAOYSA-N 7-(diethylamino)-n-[2-[(2-iodoacetyl)amino]ethyl]-2-oxochromene-3-carboxamide Chemical compound C1=C(C(=O)NCCNC(=O)CI)C(=O)OC2=CC(N(CC)CC)=CC=C21 OGQHCUYSWDOIMP-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 81
- 230000009931 harmful effect Effects 0.000 claims abstract description 28
- 230000000968 intestinal effect Effects 0.000 claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 4
- 235000013373 food additive Nutrition 0.000 claims abstract description 3
- 239000002778 food additive Substances 0.000 claims abstract description 3
- 235000013618 yogurt Nutrition 0.000 claims abstract description 3
- 241000186660 Lactobacillus Species 0.000 claims description 92
- 229940039696 lactobacillus Drugs 0.000 claims description 90
- 239000000203 mixture Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000014548 Rubus moluccanus Nutrition 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 abstract description 31
- 210000000936 intestine Anatomy 0.000 abstract description 8
- 230000000529 probiotic effect Effects 0.000 abstract description 8
- 244000005700 microbiome Species 0.000 abstract description 6
- 241001468157 Lactobacillus johnsonii Species 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 abstract description 5
- 235000018291 probiotics Nutrition 0.000 abstract description 5
- 206010016952 Food poisoning Diseases 0.000 abstract description 4
- 208000019331 Foodborne disease Diseases 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 76
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 42
- 239000004310 lactic acid Substances 0.000 description 38
- 235000014655 lactic acid Nutrition 0.000 description 38
- 239000002609 medium Substances 0.000 description 31
- 235000019152 folic acid Nutrition 0.000 description 23
- 239000011724 folic acid Substances 0.000 description 23
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 21
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 21
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 19
- 229960000304 folic acid Drugs 0.000 description 19
- 108020004465 16S ribosomal RNA Proteins 0.000 description 18
- 239000003613 bile acid Substances 0.000 description 17
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229960000723 ampicillin Drugs 0.000 description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 241000194017 Streptococcus Species 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100036430 Glycophorin-B Human genes 0.000 description 6
- 101001071776 Homo sapiens Glycophorin-B Proteins 0.000 description 6
- 244000199866 Lactobacillus casei Species 0.000 description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229940017800 lactobacillus casei Drugs 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000193403 Clostridium Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940014144 folate Drugs 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000606357 Johnsonia Species 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- NNDHDYDFEDRMGH-CAEIVAEBSA-N Anthranoyllycoctonine Chemical compound C([C@]12CN(C3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N NNDHDYDFEDRMGH-CAEIVAEBSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- ODFCHNSNEOLWKC-UHFFFAOYSA-N CC(O)C(O)=O.N1C(=O)NC(=O)C2=C1NC(=O)N2 Chemical compound CC(O)C(O)=O.N1C(=O)NC(=O)C2=C1NC(=O)N2 ODFCHNSNEOLWKC-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- UXOXDDUEWZOAIW-UHFFFAOYSA-N Inuline Natural products CCN1CC2(CC(=O)Oc3ccccc3N)CCC(OC)C45C6CC7C(CC(O)(C6C7OC)C(O)(C(OC)C24)C15)OC UXOXDDUEWZOAIW-UHFFFAOYSA-N 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- -1 L-Sorbitol - Rhamnose Chemical compound 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- VNRZCPPHNPEBFC-UHFFFAOYSA-N anthranoyllycoctonine Natural products CCN1CC2(COC(=O)c3ccccc3N)CCC(OC)C45C2C(OC)C(O)(C14)C6(O)CC(OC)C7CC5(O)C6C7OC VNRZCPPHNPEBFC-UHFFFAOYSA-N 0.000 description 1
- 238000002829 antibacterial sensitivity test Methods 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- SUSRLLXAXAIZPH-OBPIAQAESA-N hydroquinone beta-D-glucopyranoside Natural products OC[C@H]1O[C@@H](Cc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O SUSRLLXAXAIZPH-OBPIAQAESA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
pH 유산균 | pH 2.3 (× 109 CFU/㎖) | pH 2.5 (× 109 CFU/㎖) | ||||
0 시간 | 1 시간 | 2 시간 | 0 시간 | 1 시간 | 2 시간 | |
Lb . rhamnosus GG | 3.5 | 2.1 | 1.9 | 3.5 | 2.3 | 2.0 |
IDCC 9203 | 4.2 | 3.2 | 2.8 | 4.2 | 3.2 | 3.0 |
Bile 첨가여부 유산균 | Control 0.3% bile 비첨가 (× 109 CFU/㎖) | 0.3% bile 첨가 (× 109 CFU/㎖) |
Lb . rhamnosus GG | 5.7 | 1.8 |
IDCC 9203 | 8.9 | 2.5 |
시험균명 | 최소발육저지 농도(MIC %) | |
Lb . rhamnosus GG | IDCC 9203 | |
1. S. aureus Met R | 1.25 | 2.50 |
2. S. aureus Met S | 2.50 | 2.50 |
3. Coagulans negative S.Met R | 2.50 | 2.50 |
4. Coagulans negative S.Met S | 2.50 | 2.50 |
5. Enterococcus faecalis Van R | 5.00 | 5.00 |
6. Enterococcus faecalis Van S | 2.50 | 2.50 |
7. Enterococcus faecium Van R | 1.25 | 1.25 |
8. Enterococcus faecium Van S | 1.25 | 1.25 |
9. Str . agalactiae | 1.25 | 2.50 |
10.Str . faecium MD 8ba | 1.25 | 1.25 |
11.Klebsiella pneumoniae ESBL | 2.50 | 2.50 |
12.Escherichia coli DC0 | 2.50 | 1.25 |
13.Escherichia coli DC2 | 1.25 | 1.25 |
14.Escherichia coli TEM | 2.50 | 1.25 |
15.Pseudomonas aeruginosa 9207 | 1.25 | 1.25 |
16.Pseudomonas aeruginosa 1592E | 1.25 | 1.25 |
17.Klebsiella aerogenes 1522E | 2.50 | 2.50 |
18.Enterobacter cloacae P99 | 2.50 | 1.25 |
19.Enterobacter cloacae 1321E | 2.50 | 2.50 |
유산균 주 | Control (CFU/g feces) | Lb . rhamnosus GG (CFU/g feces) | IDCC 9203 (CFU/g feces) | |
적응기 | 0 | 2.00 × 109 | 2.00 × 109 | 1.50 × 109 |
1 | 1.50 × 109 | 2.30 × 109 | 1.48 × 109 | |
암피실린 투여후 | 0.5 | 2.00 × 104 | 2.00 × 104 | 2.00 × 104 |
1 | 2.00 × 102 | 2.00 × 102 | 2.00 × 102 | |
유산균 투여후 | 0.5 | 2.00 × 103 | 1.58 × 106 | 3.02 × 106 |
1 | 8.90 × 103 | 8.91 × 106 | 1.00 × 107 | |
1.5 | 1.50 × 104 | 1.20 × 107 | 2.00 × 107 | |
2 | 8.90 × 102 | 2.45 × 107 | 2.69 × 107 | |
유산균투여 중단후 | 0.5 | 0 | 1.41 × 105 | 3.63 × 106 |
1 | 0 | 2.95 × 104 | 1.51 × 106 | |
1.5 | 0 | 2.00 × 104 | 2.00 × 105 | |
2 | 0 | 0 | 2.40 × 104 | |
2.5 | 0 | 0 | 2.00 × 102 |
유산균 주 | Control (CFU/g feces) | Lb . rhamnosus GG (CFU/g feces) | IDCC 9203 (CFU/g feces) | |
적응기 | 0 | 1.99 × 105 | 1.00 × 105 | 1.00 × 105 |
1 | 7.94 × 105 | 6.02 × 105 | 1.99 × 105 | |
암피실린 투여후 | 0.5 | 3.98 × 103 | 1.99 × 103 | 7.94 × 103 |
1 | 2.00 × 102 | 2.00 × 102 | 2.00 × 102 | |
유산균 투여후 | 0.5 | 2.88 × 108 | 2.23 × 108 | 6.60 × 108 |
1 | 1.69 × 109 | 1.44 × 109 | 1.23 × 109 | |
1.5 | 9.12 × 108 | 3.16 × 108 | 1.99 × 108 | |
2 | 7.94 × 108 | 3.98 × 107 | 8.91 × 106 | |
유산균투여 중단후 | 0.5 | 1.58 × 107 | 7.94 × 105 | 7.94 × 105 |
1 | 3.23 × 106 | 7.41 × 105 | 2.39 × 105 | |
1.5 | 1.04 × 107 | 2.18 × 106 | 3.16 × 105 | |
2 | 3.01 × 106 | 2.81 × 106 | 1.77 × 105 | |
2.5 | 1.41 × 106 | 6.16 × 106 | 1.58 × 105 |
유산균 주 | Control (CFU/g feces) | Lb. rhamnosus GG (CFU/g feces) | IDCC 9203 (CFU/g feces) | |||
적응기 | 0 | 1.58 × 106 | 2.57 × 106 | 4.26 × 106 | ||
1 | 1.41 × 106 | 3.80 × 106 | 1.81 × 106 | |||
암피실린 투여후 | 0.5 | 3.98 × 103 | 7.94 × 103 | 8.91 × 102 | ||
1 | 2.00 × 102 | 2.00 × 102 | 2.00 × 102 | |||
유산균 투여후 | 0.5 | 8.91 × 104 | 8.91 × 104 | 8.91 × 104 | ||
1 | 3.23 × 108 | 2.39 × 108 | 1.28 × 108 | |||
1.5 | 3.01 × 109 | 1.04 × 109 | 1.00 × 109 | |||
2 | 2.23 × 109 | 6.02 × 107 | 1.99 × 107 | |||
유산균투여 중단후 | 0.5 | 1.34 × 109 | 4.78 × 108 | 7.76 × 108 | ||
1 | 2.23 × 108 | 3.23 × 106 | 3.16 × 108 | |||
1.5 | 1.81 × 109 | 7.94 × 106 | 4.16 × 108 | |||
2 | 3.01 × 109 | 1.25 × 107 | 3.63 × 107 | |||
2.5 | 2.39 × 109 | 7.94 × 107 | 1.99 × 106 |
유산균 주 | Control (CFU/g feces) | Lb . rhamnosus GG (CFU/g feces) | IDCC 9203 (CFU/g feces) | ||
적응기 | 0 | 9.12 × 108 | 6.02 × 107 | 1.00 × 108 | |
1 | 3.98 × 108 | 1.81 × 108 | 1.09 × 108 | ||
암피실린 투여후 | 0.5 | 3.98 × 106 | 1.99 × 106 | 3.98 × 106 | |
1 | 2.00 × 102 | 2.00 × 102 | 2.00 × 102 | ||
유산균 투여후 | 0.5 | 1.77 × 108 | 2.39 × 108 | 1.12 × 109 | |
1 | 5.01 × 109 | 3.80 × 109 | 3.54 × 109 | ||
1.5 | 4.16 × 109 | 1.86 × 109 | 1.58 × 109 | ||
2 | 2.04 × 109 | 5.01 × 107 | 9.77 × 108 | ||
유산균투여 중단후 | 0.5 | 1.47 × 109 | 1.99 × 107 | 7.76 × 107 | |
1 | 1.41 × 107 | 3.01 × 107 | 3.98 × 107 | ||
1.5 | 3.98 × 106 | 6.60 × 106 | 1.77 × 107 | ||
2 | 9.33 × 106 | 7.94 × 106 | 2.18 × 107 | ||
2.5 | 1.99 × 106 | 3.01 × 107 | 6.02 × 106 |
희석배수 | 비장 | 간 | 혈액 |
10-1 | - | - | - |
10-2 | - | - | - |
10-3 | - | - | - |
Control | - | Glycerol | - | Erythritol | - | D-Arabinose | - | L-Arabinose | - |
Ribose | - | D-Xylose | - | L-Xylose | - | Adonitol | - | β-Methyl-xyloside | - |
Galactose | + | D-Glucose | + | D-Fructose | + | D-Mannose | + | L-Sorbitol | - |
Rhamnose | - | Dulcitol | - | Inositol | - | Mannitol | - | Sorbitol | - |
α-Methyl-D-mannoside | - | α-Methyl-D-glucoside | - | N-Acetyl glucosamine | + | Amygdaline | - | Arbutine | - |
Esculine | + | Salicine | - | Cellobiose | - | Maltose | + | Lactose | + |
Melibiose | - | Saccharose | + | Trehalose | + | Inuline | - | Melezitose | - |
D-Raffinose | + | Amidon | + | Glycogen | - | Xylitol | - | β-Gentibiose | + |
D-Turanose | - | D-Lyxose | - | D-Tagatose | +/- | D-Fucose | - | L-Fucose | - |
D-Arabitol | - | L-Arabitol | - | Gluconate | - | 2-ceto-gluconate | - | 5-ceto-gluconate | - |
이름 | 목표 | 위치 | 염기 배열 순서 |
ID8-F | 16S rRNA | 1-19 | 서열번호 1 |
ID8-R | 16S rRNA | 1512-1531 | 서열번호 2 |
T7-F | pcDNA3.1 | ㆍ | 서열번호 3 |
BGH-R | pcDNA3.1 | ㆍ | 서열번호 4 |
ID13S-F | 16S rRNA | 530-547 | 서열번호 5 |
종료 pH | 배양액 생균수 (× 108 CFU/㎖) | 원료 생균수 (× 108 CFU/㎖) | 발현율(%) |
4.2 | 80 | 250 | 42.9 |
Antimicrobial agents | Disc conc. (㎍) | Clear zone Diameter (㎜) | Interpretative zone diameter(mm) | 판정결과 | |||
R* | I** | S*** | |||||
Penicillin | 10 | 30 | ≤19 | 20-27 | ≥28 | S | |
Ampicillin | 10 | 22 | ≤12 | 13-15 | ≥16 | S | |
Cephalothin | 30 | 30 | ≤14 | 15-17 | ≥18 | S | |
Vancomycin | 30 | 18 | ≤14 | 15-17 | ≥18 | S | |
Bacitracin | 10 | 12 | ≤15 | 16-17 | ≥18 | R | |
Amikacin | 30 | 6 | ≤15 | 16-17 | ≥18 | R | |
Gentamycin | 10 | 6 | ≤12 | - | ≥13 | R | |
Kanamycin | 30 | 6 | ≤13 | 14-17 | ≥18 | R | |
Streptomycin | 10 | 6 | ≤11 | 12-14 | ≥15 | R | |
Tetracycline | 30 | 7 | ≤14 | 15-18 | ≥19 | R | |
Chloramphenicol | 30 | 18 | ≤13 | 14-17 | ≥18 | S | |
Erythromycin | 15 | 20 | ≤13 | 14-17 | ≥18 | S | |
Oflaxacin | 5 | 6 | ≤13 | 14-18 | ≥19 | R | |
Nalidixic acid | 30 | 6 | ≤13 | 14-17 | ≥18 | R | |
Rifampin | 5 | 20 | ≤14 | 15-17 | ≥18 | S | |
Polymyxin B | 300 | 6 | ≤8 | 9-11 | ≥12 | R | |
Nitrofurantoin | 300 | 18 | ≤14 | 15-16 | ≥17 | S |
접종량 엽산생성량 | 10 ㎕ | 30 ㎕ | 50 ㎕ | 100 ㎕ |
O.D600nm | 0.313 | 0.74 | 0.747 | 0.758 |
엽산생성량(㎍/ℓ) | 2.57 | 4.35 | 4.38 | 4.43 |
Claims (4)
- 장내 유해세균 억제능을 갖는 락토바실러스 존소니이 IDCC 9203(수탁번호 : KCTC 10923BP).
- 제 1항의 균주를 유효성분으로 함유하는 정장제.
- 제 1항의 균주를 유효성분으로 함유하는 식품.
- 제 3항에 있어서, 상기 식품은 발효유, 요구르트, 음료수, 식품 첨가물및 건강 식품으로 구성되는 군으로부터 선택되는 것을 특징으로 하는 식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060047726A KR100736517B1 (ko) | 2006-05-26 | 2006-05-26 | 장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060047726A KR100736517B1 (ko) | 2006-05-26 | 2006-05-26 | 장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100736517B1 true KR100736517B1 (ko) | 2007-07-06 |
Family
ID=38503463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060047726A KR100736517B1 (ko) | 2006-05-26 | 2006-05-26 | 장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100736517B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101201420B1 (ko) | 2009-07-22 | 2012-11-15 | 대한민국 | 신규 락토바실러스 존슨니 및 이를 포함하는 사료첨가제 조성물 |
KR101231236B1 (ko) | 2011-01-24 | 2013-02-08 | 고려대학교 산학협력단 | 대두 사포닌 분해능을 갖는 유산균 및 이를 함유하는 대두 사포닌 분해용 조성물 |
KR102269964B1 (ko) | 2020-05-28 | 2021-06-28 | 주식회사 바이오뱅크힐링 | 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
KR102296288B1 (ko) | 2020-12-31 | 2021-09-01 | 주식회사 바이오뱅크힐링 | 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
WO2021242057A1 (ko) * | 2020-05-28 | 2021-12-02 | 주식회사 바이오뱅크힐링 | 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030070319A (ko) * | 2002-02-23 | 2003-08-30 | 주식회사 프로바이오닉 | 결장 암 세포 및 유해 미생물 증식 억제 활성과 장내정착력이 뛰어난 신규 내산성 락토바실러스 애시도필러스Probio-40 |
KR20030070799A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 지방질, 다당류 및 단백질에 의하여 2중으로 미세캡슐화된유산균 제품의 제조방법 |
KR20030070800A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 이중으로 미세캡슐화된 유산균 함유 우유 또는 유제품의제조방법 |
KR20040076183A (ko) * | 2003-02-24 | 2004-08-31 | 주식회사 프로바이오닉 | 면역활성이 높고 항암효과 및 유해 미생물 증식 억제활성이 뛰어난 신규 내산성 락토바실러스 사케이 Probio-44 |
-
2006
- 2006-05-26 KR KR1020060047726A patent/KR100736517B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030070319A (ko) * | 2002-02-23 | 2003-08-30 | 주식회사 프로바이오닉 | 결장 암 세포 및 유해 미생물 증식 억제 활성과 장내정착력이 뛰어난 신규 내산성 락토바실러스 애시도필러스Probio-40 |
KR20030070799A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 지방질, 다당류 및 단백질에 의하여 2중으로 미세캡슐화된유산균 제품의 제조방법 |
KR20030070800A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 이중으로 미세캡슐화된 유산균 함유 우유 또는 유제품의제조방법 |
KR20040076183A (ko) * | 2003-02-24 | 2004-08-31 | 주식회사 프로바이오닉 | 면역활성이 높고 항암효과 및 유해 미생물 증식 억제활성이 뛰어난 신규 내산성 락토바실러스 사케이 Probio-44 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101201420B1 (ko) | 2009-07-22 | 2012-11-15 | 대한민국 | 신규 락토바실러스 존슨니 및 이를 포함하는 사료첨가제 조성물 |
KR101231236B1 (ko) | 2011-01-24 | 2013-02-08 | 고려대학교 산학협력단 | 대두 사포닌 분해능을 갖는 유산균 및 이를 함유하는 대두 사포닌 분해용 조성물 |
KR102269964B1 (ko) | 2020-05-28 | 2021-06-28 | 주식회사 바이오뱅크힐링 | 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
WO2021242057A1 (ko) * | 2020-05-28 | 2021-12-02 | 주식회사 바이오뱅크힐링 | 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
KR102296288B1 (ko) | 2020-12-31 | 2021-09-01 | 주식회사 바이오뱅크힐링 | 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100911115B1 (ko) | 내산성, 내담즙산성 및 항균 효과를 가진 신규한 유산균 및 이를 포함하는 조성물 | |
EP1743042B1 (en) | Lactic acid bacteria strains exhibiting probiotic properties and compositions comprising the same | |
EP2270133B1 (en) | Method for obtaining a novel strain of bifidobacterium bifidum with activity against infection by helicobacter pylori | |
KR20200136365A (ko) | 공동선택 미생물총을 포함하는 조성물 및 그 이용 방법 | |
EP1883695B1 (en) | Probiotic bifidobacterial species | |
KR100736517B1 (ko) | 장내 유해세균 억제능을 갖는 락토바실루스 존소니이 아이디씨씨 9203 | |
Gao et al. | Screening of potential probiotics with anti-Helicobacter pylori activity from infant feces through principal component analysis | |
Azizian et al. | Genetic diversity of Lactobacillus spp. isolates from oral cavity and their probiotic and antimicrobial properties | |
KR101966772B1 (ko) | 락토바실러스 루테리 cs 132(kctc 11452bp) 또는 이의 배양물을 포함하는 구강병원균 억제조성물 | |
KR101098946B1 (ko) | 신규한 락토바실러스 살리바리우스 균주 및 이를 함유하는 사료첨가제 조성물 | |
KR101201338B1 (ko) | 신규 락토바실러스 루테리 및 이를 포함하는 사료첨가제 조성물 | |
KR100240687B1 (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
KR101061143B1 (ko) | 신규 유산균 및 그 유산균을 사용해서 가공한 각종 제품 | |
Zangeneh et al. | Isolation of Lactobacillus plantarum strains with robust antagonistic activity, qualified probiotic properties, and without antibiotic-resistance from traditional sourdough | |
EP3318625B1 (en) | A lactic acid bacteria strain | |
EP2040723B1 (en) | Lactic acid bacterium with increased acid tolerance | |
KR20190075039A (ko) | 락토바실러스 플란타룸 kcc-24 및 이를 포함하는 조성물 | |
KR101201337B1 (ko) | 신규한 락토바실러스속 유산균 복합 균주를 포함하는 사료첨가제 | |
KR100720025B1 (ko) | 프로바이오틱 유산균 및 이를 포함하는 조성물 | |
KR100825500B1 (ko) | 경구 운반체의 개발을 위한 돼지 유래 신규 유산균 및 이의용도 | |
KR101068524B1 (ko) | 락토바실러스 프란타럼 μ23 균주를 포함하는 발효유 및이의 제조방법 | |
KR20020072807A (ko) | 면역 증강 효과를 갖는 신규 락토바실러스 속 미생물 | |
KR20170045190A (ko) | 락토바실러스 플란타룸 kcc-24 및 이를 포함하는 조성물 | |
KR102010441B1 (ko) | 항균 활성과 프로바이오틱스 특성을 갖는 락토바실러스 플란타룸 srcm101502 균주 및 이의 용도 | |
KR100654370B1 (ko) | 반코마이신 내성균을 저해하는 항생제 내성 신규 유산균 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130529 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140603 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150604 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160218 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170522 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180518 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190530 Year of fee payment: 13 |